It will be of interest to determine if ETP-ALL generally relies on the BDME to drive MYC, as this would provide a rationale for treatment of ETP-ALL will BRD4 inhibitors, which are now being tested in clinical trials. Here, BRD4 is linked to acute lymphoblastic leukemia.